AGM
NAGE

Alpine Global Management’s Niagen Bioscience NAGE Stock Holding History

Alpine Global Management’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-46,363
Closed -$127K – 506
2024
Q2 		$127K Buy
+46,363
New +$155K 0.02% 375
2018
Q1 		– Sell
-20,680
Closed -$122K – 199
2017
Q4 		$122K Buy
+20,680
New +$112K 0.03% 149

Other funds holding NAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Alpine Global Management's NAGE Position: Q3 2024 in Review

Alpine Global Management sold out of Niagen Bioscience (NAGE) in Q3 2024, closing a stake of 46,363 shares — an estimated $127K sold.

Alpine Global Management first reported a position in NAGE in Q4 2017 and held it in 2 quarters. The position peaked at $127K in Q2 2024. 91 funds tracked by Wall St. Rank hold NAGE as of Q3 2024.

  • Alpine Global Management reported no remaining Niagen Bioscience position as of Q3 2024 after selling out during the quarter.
  • Alpine Global Management sold 46,363 Niagen Bioscience shares in Q3 2024, an estimated $127K.
  • Alpine Global Management first reported a position in Niagen Bioscience in Q4 2017 and held it in 2 quarters.
  • Alpine Global Management's Niagen Bioscience position peaked at $127K in Q2 2024.
  • 91 funds tracked by Wall St. Rank held Niagen Bioscience as of Q3 2024.

Based on Alpine Global Management's 13F filing for Q3 2024, filed 14 Nov 2024.